Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 27;8(10):1556. doi: 10.3390/jcm8101556

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Expression of CD4 in PZA and INH treated granulomas. CD4 T cells were measured with an anti-CD4 antibody conjugated with (Phycoerythrin-Cy5) PE-Cy5. The nuclei of cells were stained with (4’,6-diamidino-2-phenylindole) DAPI. The mean fluorescence of CD4 was corrected with the mean DAPI fluorescence. (A) CD4 mean fluorescence from non-vaccinated subjects with L-GSH treatment along with CD4 fluorescent images; (B) CD4 mean fluorescence from BCG vaccinated subjects with L-GSH treatment along with CD4 fluorescent images; (C) CD4 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in non-vaccinated subjects; (D) CD4 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (E) CD4 mean fluorescence in non-vaccinated and BCG-vaccinated groups with sham treatment and L-GSH treatment; (F) CD4 mean fluorescence in non-vaccinated and BCG-vaccinated groups with PZA treatment. Data represents ± SE from experiments performed from 14 different subjects. An unpaired t-test with Welch corrections was used in Figure (A). Analysis of Figures B–F utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to control, and an asterisk indicates categories compared to the previous category directly before it. (G) CD4 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in non-vaccinated subjects; (H) CD4 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (I) CD4 mean fluorescence in non-vaccinated and BCG-vaccinated groups with INH treatment. Data represents ± SE from experiments performed from 14 different subjects. The analysis of figures utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to the control, and an asterisk indicates categories compared to the previous category directly before it.

Expression of CD4 in PZA and INH treated granulomas. CD4 T cells were measured with an anti-CD4 antibody conjugated with (Phycoerythrin-Cy5) PE-Cy5. The nuclei of cells were stained with (4’,6-diamidino-2-phenylindole) DAPI. The mean fluorescence of CD4 was corrected with the mean DAPI fluorescence. (A) CD4 mean fluorescence from non-vaccinated subjects with L-GSH treatment along with CD4 fluorescent images; (B) CD4 mean fluorescence from BCG vaccinated subjects with L-GSH treatment along with CD4 fluorescent images; (C) CD4 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in non-vaccinated subjects; (D) CD4 mean fluorescence with PZA, 1/10 PZA, and 1/100 PZA treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (E) CD4 mean fluorescence in non-vaccinated and BCG-vaccinated groups with sham treatment and L-GSH treatment; (F) CD4 mean fluorescence in non-vaccinated and BCG-vaccinated groups with PZA treatment. Data represents ± SE from experiments performed from 14 different subjects. An unpaired t-test with Welch corrections was used in Figure (A). Analysis of Figures B–F utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to control, and an asterisk indicates categories compared to the previous category directly before it. (G) CD4 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in non-vaccinated subjects; (H) CD4 mean fluorescence with INH, 1/10 INH, and 1/100 INH treatment in the presence or absence of L-GSH in BCG-vaccinated subjects; (I) CD4 mean fluorescence in non-vaccinated and BCG-vaccinated groups with INH treatment. Data represents ± SE from experiments performed from 14 different subjects. The analysis of figures utilized a one-way ANOVA with Tukey test. The p value style consisted of 0.1234 as not significant, 0.0332 with one asterisk (*), 0.0021 with two asterisks (**), 0.0002 with three asterisks (***), and less than 0.0001 with four asterisks (****). A hash mark (#) indicates categories compared to the control, and an asterisk indicates categories compared to the previous category directly before it.